https://www.selleckchem.com/products/PD-98059.html
Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue with an extended half-life of approximately 1week has being come into clinic trial to treat parkingson's disease but little is known about its effect to prevent against Alzheimer's disease (AD). The goal of the present study was to explore the potential mechanisms of semaglutide to protect against AD. We treated SH-SY5Y cell line with Aβ as an AD model. Further, SH-SY5Y cells damaged by Aβ were treated by semaglutide. Autophagy-related proteins and apoptosis-related proteins were
Like
Comment
Share
